SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

ALS Clinical Trials Consortium (NEALS)

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-als-clinical-trials-co
Related Entities
institutions-als-clinical-trials-consortium
Metadata
sluginstitutions-als-clinical-trials-consortium
entity_typeinstitution
kg_node_idNone
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (106)
mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di75%
mentions🔬RNA binding protein dysregulation across ALS FTD AD75%
mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes75%
mentions🔬RNA binding protein dysregulation across ALS FTD and AD75%
mentions🧫cGAMP biomarker analysis in ALS patient spinal cord samples70%
mentions🧫TDP-43 mutant mouse model cGAS/STING pathway analysis70%
mentions🧫cGAMP biomarker analysis in ALS patient spinal cord samples70%
mentions🧫TDP-43 mitochondrial invasion and mtDNA release in iPSC moto70%
mentions🧫cGAS/STING pathway activation by TDP-43-released mtDNA70%
mentions🧫s:** - Temporal analysis showing mitochondrial defects prece70%
mentions🧫Proposed experiment from debate on TDP-43 undergoes liquid-l70%
mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr70%
mentions🧫Metabolic Pathway-Targeted Therapy in ALS70%
mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker70%
mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model70%
mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk70%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration70%
mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%
mentions🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka70%
mentions🧫Brainstem Circuit Modulation for PSP70%
mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT70%
mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study70%
mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen70%
mentions🧫Experiment Index70%
mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio70%
mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design70%
mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin70%
mentions🧫N-of-1 Clinical Trial Design for CBS/PSP70%
mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers70%
mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic70%
mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%
mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD70%
mentions🧫PSP and CBS Biomarker Validation Study70%
mentions🧫Experiment Scoring Methodology70%
mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen70%
mentions🧫TDP-43 PET Ligand Development for FTD and ALS70%
mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%
related🔬CRISPR-based therapeutic approaches for neurodegenerative di67%
related🔬RNA binding protein dysregulation across ALS FTD AD67%
related🔬TDP-43 undergoes liquid-liquid phase separation that becomes67%
related🔬RNA binding protein dysregulation across ALS FTD and AD67%
related🧫cGAMP biomarker analysis in ALS patient spinal cord samples63%
related🧫TDP-43 mutant mouse model cGAS/STING pathway analysis63%
related🧫cGAMP biomarker analysis in ALS patient spinal cord samples63%
related🧫TDP-43 mitochondrial invasion and mtDNA release in iPSC moto63%
related🧫cGAS/STING pathway activation by TDP-43-released mtDNA63%
related🧫s:** - Temporal analysis showing mitochondrial defects prece63%
related🧫Proposed experiment from debate on TDP-43 undergoes liquid-l63%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr63%
related🧫Metabolic Pathway-Targeted Therapy in ALS63%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker63%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model63%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk63%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration63%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%
related🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka63%
related🧫Brainstem Circuit Modulation for PSP63%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT63%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study63%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen63%
related🧫Experiment Index63%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio63%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design63%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin63%
related🧫N-of-1 Clinical Trial Design for CBS/PSP63%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers63%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic63%
related🧫Progranulin Replacement Therapy for FTD — Vector Development63%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD63%
related🧫PSP and CBS Biomarker Validation Study63%
related🧫Experiment Scoring Methodology63%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen63%
related🧫TDP-43 PET Ligand Development for FTD and ALS63%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des63%
mentions🔬What are the mechanisms underlying tdp-43 phase separation t60%
mentions🔬What are the mechanisms underlying rna binding protein dysre60%
mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di60%
mentions🔬Analyze the spectrum of microglial activation states (DAM, h60%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫Brainstem Circuit Modulation for PSP60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
related🧫PSP and CBS Biomarker Validation Study60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
related🔬What are the mechanisms underlying tdp-43 phase separation t54%
related🔬What are the mechanisms underlying rna binding protein dysre54%
related🔬CRISPR-based therapeutic approaches for neurodegenerative di54%
related🔬Analyze the spectrum of microglial activation states (DAM, h54%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub